Castle Biosciences Unveils Key Insights on Barrett’s Esophagus Test

Castle Biosciences, Inc. has announced significant findings regarding its TissueCypher® Barrett’s Esophagus test, which offers crucial insights into patient risk that extend beyond traditional pathology. The data, set to be presented at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting from October 27 to 29 in Phoenix, Arizona, suggests that the test could lead to earlier interventions for patients at higher risk of developing esophageal cancer. This innovation may also help to decrease unnecessary procedures for patients deemed to be at lower risk.

The findings will be showcased through three posters during the conference, with one of the presentations receiving a Presidential Poster Award. According to Edward Horvath, M.D., a board-certified gastroenterologist at Gastro Health West Boynton, relying solely on pathology to assess the risk of progression in patients with Barrett’s esophagus can be challenging.

Dr. Horvath stated, “By identifying patients at higher risk who may otherwise be missed, the TissueCypher test provides objective, individualized risk information that supports more personalized decisions around surveillance and intervention.” This approach allows clinicians to act more promptly, potentially reducing the risk of progression to esophageal cancer.

The TissueCypher test functions by evaluating the biological characteristics of Barrett’s esophagus tissues, thereby delivering a more nuanced understanding of the risk of progression to cancer. This is particularly critical given that esophageal cancer is often diagnosed at advanced stages, where treatment options become limited.

Incorporating these insights into clinical decision-making could significantly enhance patient care. It enables healthcare providers to tailor their surveillance protocols based on individual risk levels, which may ultimately lead to better outcomes and more efficient use of medical resources.

The implications of this research extend beyond individual patients. As healthcare systems worldwide continue to navigate the challenges posed by rising cancer rates, integrating innovative diagnostic tools like the TissueCypher test into routine practice could represent a meaningful step towards more effective cancer prevention strategies.

Castle Biosciences remains committed to advancing the field of oncology through its innovative tests. The company’s ongoing research and commitment to patient care exemplify how new technologies can reshape the landscape of cancer diagnostics and management. The upcoming presentation at the ACG meeting represents a pivotal moment for Castle Biosciences as it seeks to establish its mark in the gastroenterology domain.